However, more research is needed to determine if other chemotherapeutic agents are more effective than oxaliplatin used with HIPEC in this study and if there are certain subsets of patients who would still benefit from receiving HIPEC with surgery. Specifically, a subgroup analysis from this study suggested that HIPEC might be beneficial for patients with a mid-range peritoneal cancer index (11–15), but the numbers were too small to be conclusive. People with alow peritoneal cancer index can likely forgo HIPEC, whereas those with a high index may not benefit from either surgery or HIPEC